Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST
Company Participants
Susan Morrison – Executive VP & Chief Administrative Officer
John Sheridan – President, CEO & Director
Leigh Vosseller – Executive VP, CFO & Treasurer
Conference Call Participants
Matthew Miksic – Barclays Bank PLC, Research Division
Larry Biegelsen – Wells Fargo Securities, LLC, Research Division
Christopher Pasquale – Nephron Research LLC
Danielle Antalffy – UBS Investment Bank, Research Division
Michael Kratky – Leerink Partners LLC, Research Division
Joanne Wuensch – Citigroup Inc. Exchange Research
Suraj Kalia – Oppenheimer & Co. Inc., Research Division
William Plovanic – Canaccord Genuity Corp., Research Division
Michael Polark – Wolfe Research, LLC
Jeffrey Johnson – Robert W. Baird & Co. Incorporated, Research Division
Stephanie Piazzola – BofA Securities, Research Division
Jonathan Block – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Susan Morrison, Executive Vice President and Chief Administrative Officer. Please go ahead.
Susan Morrison
Executive VP & Chief Administrative Officer
Hello, everyone, and welcome to Tandem’s Third Quarter 2025 Earnings Call. Today’s discussion will include forward-looking statements. These statements reflect management’s expectations about future events, our product pipeline, development timelines and financial performance and operating plans and speak only as of today’s date.
There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements, which are described in our press release issued earlier today and under the Risk Factors portion of our most recent quarterly report on Form 10-Q.
Today’s discussion will also include references to both GAAP and non-GAAP financial measures. Please refer
Read the full article here